Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

rded.

Research and development expenses for the first quarter ended March 31, 2010 were $6.4 million, compared to $1.7 million in the corresponding period of 2009. The increased research and development expenses resulted from OncoGenex's contribution to the OGX-011 Phase III clinical trials in the amount of $1.9 million and manufacturing costs in the amount of $2.8 million, the latter of which is reimbursable from Teva.

General and administrative expenses for the first quarter ended March 31, 2010 were $1.4 million, compared to $0.8 million in the corresponding period of 2009. The increase in the first quarter of 2010 was due mainly to higher employee expenses including severance charges, professional fees for legal and accounting services, employee recruitment costs and stock based compensation expense.

The net loss for the first quarter ended March 31, 2010 was $3.0 million, compared to $2.4 million in the corresponding period of 2009.

The Company had $47.6 million in cash, cash equivalents and short-term investments as of March 31, 2010, compared to $64.6 million at December 31, 2009. The decrease in cash, cash equivalents, and short-term investments is primarily due to costs incurred in the first quarter of 2010 relating to the OGX-011 development plan, and the $10 million payment made to Isis in the first quarter of 2010, which was included in accounts payable as a
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... SOUTH SAN FRANCISCO, Calif. , May 20, ... VCYT ) today presented preliminary data demonstrating ... help distinguish idiopathic pulmonary fibrosis (IPF) from other ... bronchoscopy. The findings suggest the classifier,s potential to ... expensive surgery to resolve ambiguity in IPF diagnosis ...
(Date:5/20/2015)...  Select Medical Corporation ("Select") (NYSE: SEM ... early termination of the waiting period under the ... amended, applicable to the acquisition of Concentra Inc. ... that Select has created with Welsh, Carson, Anderson & ... MJ Acquisition Corporation has signed a definitive purchase ...
(Date:5/20/2015)...  Marc Tessier-Lavigne, president of The Rockefeller University, ... from The Marie-Josée and Henry R. Kravis Foundation ... will be the centerpiece of the University,s major ... Kravis Research Building, two stories high, will be ... city blocks following the shoreline of the East ...
(Date:5/20/2015)... 19, 2015 Research and Markets ... the "Bone Morphogenetic Proteins Market (Types : ... and Oral - Maxillofacial) - Global Industry Analysis, ... 2022" report to their offering. ... based on the types of recombinant BMPs, applications, ...
Breaking Biology Technology:Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2
... May 15, 2012 Cardium Therapeutics (NYSE Amex: ... the first quarter ended March 31, 2012, and other ... In addition to the announcement of first ... 2012, which were outlined in the year-end report, and ...
... bioreactor holding human cells pumped out an anti-inflammatory protein ... rat with acute inflammation caused by bacterial products in ... researchers at the University of Pittsburgh School of Medicine ... were published today in the inaugural issue of ...
... DENVER, May 14, 2012 Regenerative Sciences, Inc., ... non-surgical adult stem cell procedures, today announced that ... visionary and businessman John C. Malone, PhD, chairman ... Regenerative Sciences, clinical and lab-based stem cell research, ...
Cached Biology Technology:Cardium Presents First Quarter 2012 Financial Results and Recent Developments 2Cardium Presents First Quarter 2012 Financial Results and Recent Developments 3Cardium Presents First Quarter 2012 Financial Results and Recent Developments 4Cardium Presents First Quarter 2012 Financial Results and Recent Developments 5Cardium Presents First Quarter 2012 Financial Results and Recent Developments 6Cardium Presents First Quarter 2012 Financial Results and Recent Developments 7Cardium Presents First Quarter 2012 Financial Results and Recent Developments 8Cardium Presents First Quarter 2012 Financial Results and Recent Developments 9Cardium Presents First Quarter 2012 Financial Results and Recent Developments 10Cardium Presents First Quarter 2012 Financial Results and Recent Developments 11Bio-hybrid device acts as 'thermostat' to control systemic inflammation in sepsis 2Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives 2
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
(Date:4/27/2015)... 27, 2015  For more than four decades, AUVSI,s ... been the premier worldwide event for the unmanned land, ... must-attend event for any local, national, or trade news ... commercial markets and current applications of unmanned technologies. The ... projected $48 billion industry, and how it will soon ...
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... Manchester Metropolitan University have carried out the first comparative ... than 30 millions years ago. , The study of ... (Caribbean) regions has revealed new insights into the ecologies ... It is the first time ancient spiders from different ...
... thought to play a role solely in the innate immune ... will be published on-line by the Proceedings of the National ... January 23, researchers showed for the first time that the ... tract and lungs, is linked to the control of malignant ...
... report describing the occurrence of pesticides in streams and ... are typically present throughout the year in most streams ... are less common in ground water. The report ... to affect humans. However in many streams, particularly ...
Cached Biology News:Amber reveals ecology of 30 million year old spiders 2Protein found to control tumor growth in certain breast cancers 2Pesticides in the nation's streams and ground water 2Pesticides in the nation's streams and ground water 3Pesticides in the nation's streams and ground water 4
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
HOXC11 Antibody...
HOXC11 Antibody...
Biology Products: